{"product_id":"how-a-cholesterol-medication-that-bypasses-statin-side-effects-shrunk-dangerous-heart-plaque-a-patients-success-story","title":"How a Cholesterol Medication That Bypasses Statin Side Effects Shrunk Dangerous Heart Plaque: A Patient's Success Story","description":"\u003cp\u003eThis case report describes a 66-year-old woman with coronary artery disease who could not take statins or ezetimibe due to severe side effects, but achieved remarkable success with a newer medication called bempedoic acid. Her LDL cholesterol (the \"bad\" cholesterol) dropped from an initial level of 162 mg\/dl to just 34–38 mg\/dl, and follow-up CT scans showed that dangerous soft plaque in her coronary arteries actually shrank and stabilized over 20 months. This is the first reported case showing favorable plaque changes from bempedoic acid monotherapy using serial coronary CT angiography (CCTA), offering hope for patients who are intolerant to standard cholesterol medications.\u003c\/p\u003e\n\n\u003ch1\u003eHow a Cholesterol Medication That Bypasses Statin Side Effects Shrunk Dangerous Heart Plaque: A Patient's Success Story\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#case-details\"\u003eThe Patient's Journey: A 66-Year-Old Woman with Heart Disease and Medication Intolerance\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#imaging-findings\"\u003eWhat the CT Scans Revealed: Plaque Shrinkage Over 20 Months\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#discussion\"\u003eUnderstanding Bempedoic Acid: How It Works and What Studies Show\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations: What This Case Couldn't Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eA 66-year-old woman with coronary disease and statin\/ezeitimibe intolerance achieved LDL drop from 162 to 34–38 mg\/dl on bempedoic acid alone.\u003c\/li\u003e\n\u003cli\u003eFollow-up CT scans after 20 months showed shrinkage of soft, dangerous coronary plaque and stabilization of a moderate blockage.\u003c\/li\u003e\n\u003cli\u003eBempedoic acid works differently from statins, reducing cholesterol synthesis upstream and causing fewer muscle side effects.\u003c\/li\u003e\n\u003cli\u003eIn statin-intolerant patients, bempedoic acid lowers LDL by about 23% alone, and over 40% with ezetimibe; this patient was a 'hyper-responder' receiving over 80% reduction.\u003c\/li\u003e\n\u003cli\u003eThis is a single case report; individual responses vary, and a large trial called LOCATE is ongoing to further investigate plaque changes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eCholesterol-lowering therapy is the cornerstone of treatment for atherosclerotic cardiovascular disease — a condition where fatty deposits build up inside artery walls, restricting blood flow and increasing the risk of heart attacks and strokes. Extensive clinical and experimental evidence has shown that low-density lipoprotein (LDL), often called the \"bad cholesterol,\" plays a central role in this process of atherosclerosis (hardening and narrowing of the arteries).\u003c\/p\u003e\n\n\u003cp\u003eCurrent guidelines from the European Society of Cardiology recommend that patients at very high risk for atherosclerotic cardiovascular disease achieve an LDL cholesterol reduction of \u003cstrong\u003emore than 50% from baseline\u003c\/strong\u003e and reach an LDL goal of \u003cstrong\u003ebelow 55 mg\/dl\u003c\/strong\u003e, both in primary prevention (before heart disease develops) and secondary prevention (after heart disease is already diagnosed).\u003c\/p\u003e\n\n\u003cp\u003eUntil recently, statins have been the primary medications used to achieve these goals. However, a significant number of patients cannot tolerate statins due to muscle pain and other side effects, leaving them without adequate treatment. This case report focuses on an alternative — a newer drug called \u003cstrong\u003ebempedoic acid\u003c\/strong\u003e — and provides visual evidence of its benefits using advanced heart imaging.\u003c\/p\u003e\n\n\u003cp\u003eThe imaging technology used here, \u003cstrong\u003ecoronary computed tomography angiography (CCTA)\u003c\/strong\u003e, has emerged as the central non-invasive imaging technique not only for detecting significant coronary artery disease but also for evaluating the composition of atherosclerotic plaque within the arterial wall. This is important because total \u003cstrong\u003elow-attenuation plaque burden\u003c\/strong\u003e (soft, dangerous plaque that is more prone to rupture) was reported as the most robust predictor of death and myocardial infarction (heart attack), beyond stenosis severity (how narrowed the artery is) in patients with coronary artery disease.\u003c\/p\u003e\n\n\u003ch2 id=\"case-details\"\u003eThe Patient's Journey: A 66-Year-Old Woman with Heart Disease and Medication Intolerance\u003c\/h2\u003e\n\n\u003ch3\u003eInitial Presentation in March 2017\u003c\/h3\u003e\n\n\u003cp\u003eA 66-year-old woman was initially referred to an outpatient cardiology center in March 2017 with suspected coronary artery disease (CAD). She was experiencing \u003cstrong\u003eexertional angina\u003c\/strong\u003e (chest pain triggered by physical activity) classified as CCS class II, along with shortness of breath. Her medical history included:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eArterial hypertension\u003c\/strong\u003e (high blood pressure), treated with 5 mg of ramipril per day\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHyperlipidemia\u003c\/strong\u003e (high cholesterol), treated for 2 years with 10 mg of simvastatin, with an initial LDL cholesterol level of \u003cstrong\u003e162 mg\/dl\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eHer electrocardiogram (ECG) showed normal findings. An echocardiogram revealed mild myocardial hypertrophy (thickening of the heart muscle) but normal ventricular diameters and function, with a \u003cstrong\u003eleft ventricular ejection fraction of 62%\u003c\/strong\u003e (meaning her heart was pumping blood effectively).\u003c\/p\u003e\n\n\u003cp\u003eBecause of her symptoms and an intermediate pre-test probability of \u003cstrong\u003e16%\u003c\/strong\u003e for coronary artery disease, doctors performed a \u003cstrong\u003evasodilator stress cardiac magnetic resonance (CMR)\u003c\/strong\u003e scan. This test showed myocardial perfusion abnormalities (reduced blood flow) in the septal and inferior walls of the heart. Fortunately, no myocardial scars were detected through late gadolinium enhancement imaging.\u003c\/p\u003e\n\n\u003cp\u003eDue to inducible myocardial ischemia (reduced blood flow triggered by stress) in two heart segments, along with persistent symptoms, a coronary angiography (invasive X-ray imaging of the heart's arteries) was performed, confirming \u003cstrong\u003ehigh-grade lesions (severe blockages) in the left anterior descending artery (LAD)\u003c\/strong\u003e and the \u003cstrong\u003eright coronary artery (RCA)\u003c\/strong\u003e. Percutaneous coronary intervention (PCI) — a procedure to open blocked arteries, typically with stents — was performed in both arteries, resulting in complete resolution of her angina symptoms.\u003c\/p\u003e\n\n\u003ch3\u003eStatin Troubles Begin\u003c\/h3\u003e\n\n\u003cp\u003eAfter the procedure, her lipid-lowering treatment was changed to \u003cstrong\u003e20 mg of atorvastatin per day\u003c\/strong\u003e. This resulted in an LDL cholesterol of \u003cstrong\u003e101 mg\/dl in July 2017\u003c\/strong\u003e and \u003cstrong\u003e118 mg\/dl in October 2017\u003c\/strong\u003e. Since the target value of \u003cstrong\u003ebelow 70 mg\/dl\u003c\/strong\u003e recommended by the 2016 guidelines could not be achieved, doctors added \u003cstrong\u003e10 mg of ezetimibe\u003c\/strong\u003e — another cholesterol-lowering medication that works by blocking cholesterol absorption in the gut — to her regimen. This did not significantly affect her LDL cholesterol, which was measured at \u003cstrong\u003e113 mg\/dl in April 2018\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eA Diagnosis of Statin-Associated Muscle Symptoms\u003c\/h3\u003e\n\n\u003cp\u003eIn June 2018, the patient began experiencing \u003cstrong\u003eunsteadiness, weakness, hypoesthesia (reduced sensation), and muscle pain in both legs\u003c\/strong\u003e. An electrophysiology examination of her peripheral muscles revealed no detectable neurologic abnormalities, so doctors suspected \u003cstrong\u003estatin-associated muscle symptoms (SAMS)\u003c\/strong\u003e — a well-recognized side effect of statin medications.\u003c\/p\u003e\n\n\u003cp\u003eAtorvastatin (20 mg per day) was changed to \u003cstrong\u003epravastatin (10 mg per day)\u003c\/strong\u003e, which led to clinical improvement of her muscle symptoms. However, her LDL cholesterol remained high, measuring \u003cstrong\u003e143 mg\/dl in October 2018\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eIn March 2019, the patient was referred to rheumatologists due to a recurrence of her muscle symptoms. Here, doctors diagnosed \u003cstrong\u003esmall fiber neuropathy (SFN)\u003c\/strong\u003e associated with \u003cstrong\u003eanti-Mi-2 autoantibody-positive myositis\u003c\/strong\u003e (a type of inflammatory muscle disease). Since SFN can have several causes — including diabetes, anti-retroviral medications, hypothyroidism, and hyperlipidemia — and has also been associated with statin therapy, her pravastatin was discontinued. Her muscle symptoms further improved, and she was continued on ezetimibe (10 mg per day) alone.\u003c\/p\u003e\n\n\u003cp\u003eDuring the period from March 2019 to December 2020, her LDL cholesterol remained above the desired target, ranging between \u003cstrong\u003e102 and 124 mg\/dl\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eA New Medication and New Imaging\u003c\/h3\u003e\n\n\u003cp\u003eIn March 2021, the patient reported new onset of \u003cstrong\u003eatypical angina\u003c\/strong\u003e (chest pain not clearly related to exertion) accompanied by exertional shortness of breath. Additionally, ezetimibe intolerance was suspected due to nausea.\u003c\/p\u003e\n\n\u003cp\u003eA CCTA was performed using a third-generation dual-source CT scanner (SOMATOM Force, Siemens Healthineers). This scan showed:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ePatent (open) stents in the LAD and RCA\u003c\/li\u003e\n  \u003cli\u003eNo other high-grade blockages\u003c\/li\u003e\n  \u003cli\u003eA \u003cstrong\u003emoderate stenosis (narrowing) in the distal RCA\u003c\/strong\u003e, composed of both non-calcified and calcified components\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe plaque was located directly at the crux of the RCA (where the artery bends around the bottom of the heart), resulting in a moderate \u003cstrong\u003e50–70% diameter stenosis\u003c\/strong\u003e, classified as a \u003cstrong\u003ecoronary artery disease reporting and data system (CAD-RADS) 2.0 score of 3\u003c\/strong\u003e (meaning moderate blockage). A repeated stress CMR showed normal perfusion, so invasive angiography was deferred.\u003c\/p\u003e\n\n\u003ch2 id=\"imaging-findings\"\u003eWhat the CT Scans Revealed: Plaque Shrinkage Over 20 Months\u003c\/h2\u003e\n\n\u003cp\u003eBecause of the patient's recurrent atypical symptoms, doctors discontinued ezetimibe due to recurrent nausea and started treatment with \u003cstrong\u003ebempedoic acid\u003c\/strong\u003e. The results were dramatic:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eIn \u003cstrong\u003eNovember 2021\u003c\/strong\u003e, after treatment with bempedoic acid alone, her LDL cholesterol dropped to \u003cstrong\u003e34 mg\/dl\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eIn \u003cstrong\u003eDecember 2022\u003c\/strong\u003e, her LDL remained low at \u003cstrong\u003e38 mg\/dl\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eSince the LDL target from current guidelines was now achieved, treatment with bempedoic acid was continued, and treatment with \u003cstrong\u003ePCSK9 inhibitors\u003c\/strong\u003e (a more expensive injectable cholesterol medication) was deferred.\u003c\/p\u003e\n\n\u003cp\u003eA follow-up CCTA examination was performed in \u003cstrong\u003eDecember 2022 — 20 months after the initial CCTA\u003c\/strong\u003e — using the same third-generation dual-source CT scanner. The results were remarkable:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eThe stents in the LAD and proximal RCA remained patent (open)\u003c\/li\u003e\n  \u003cli\u003eThe moderate lesion in the distal RCA showed signs of \u003cstrong\u003eplaque stabilization\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003ecalcified plaque component remained similar\u003c\/strong\u003e (visible on follow-up scans)\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003elow-attenuation (soft, dangerous) plaque component was now barely detectable\u003c\/strong\u003e — a sign of plaque shrinkage\u003c\/li\u003e\n  \u003cli\u003eThe resultant lumen narrowing (blockage) was now considered only mild, causing about \u003cstrong\u003e25–50% diameter stenosis\u003c\/strong\u003e, downgraded to a \u003cstrong\u003eCAD-RADS 2.0 score of 2\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe patient continued on treatment with \u003cstrong\u003e180 mg of bempedoic acid daily\u003c\/strong\u003e, and her clinical course over the next 4 months was uneventful.\u003c\/p\u003e\n\n\u003ch2 id=\"discussion\"\u003eUnderstanding Bempedoic Acid: How It Works and What Studies Show\u003c\/h2\u003e\n\n\u003cp\u003eThis case is, to the authors' knowledge, \u003cstrong\u003ethe first in the current literature to report favorable plaque component modification\u003c\/strong\u003e using serial CCTA studies in a patient where bempedoic acid monotherapy achieved substantial LDL reduction — a result that could not be achieved with multiple statins and ezetimibe due to intolerance.\u003c\/p\u003e\n\n\u003ch3\u003eThe Mechanism of Action\u003c\/h3\u003e\n\n\u003cp\u003eBempedoic acid is a \u003cstrong\u003enon-statin lipid-lowering drug\u003c\/strong\u003e that prevents cholesterol synthesis by inhibiting the action of \u003cstrong\u003eadenosine triphosphate (ATP) citrate lyase\u003c\/strong\u003e — a cytosolic enzyme that works upstream of the enzyme targeted by statins (HMG-CoA reductase). Because it works at a different point in the cholesterol production pathway, it is associated with a \u003cstrong\u003elow incidence of muscle-related adverse events\u003c\/strong\u003e, making it an attractive option for patients who cannot tolerate statins.\u003c\/p\u003e\n\n\u003ch3\u003eWhat Prior Studies Have Shown\u003c\/h3\u003e\n\n\u003cp\u003eThe authors cite several important studies that provide context for this case:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eIn monotherapy for patients with statin intolerance, bempedoic acid reduces LDL levels by \u003cstrong\u003e23%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eLDL reduction may exceed \u003cstrong\u003e40%\u003c\/strong\u003e when bempedoic acid is combined with ezetimibe\u003c\/li\u003e\n  \u003cli\u003eThe recent \u003cstrong\u003eCLEAR Outcomes study\u003c\/strong\u003e showed that treatment with bempedoic acid in statin-intolerant patients was associated with a \u003cstrong\u003elower risk of major adverse cardiovascular events\u003c\/strong\u003e — specifically the composite endpoint of death from cardiovascular causes, non-fatal myocardial infarction (heart attack), non-fatal stroke, and coronary revascularization\u003c\/li\u003e\n  \u003cli\u003ePrevious studies reported the ability of bempedoic acid to reduce \u003cstrong\u003ehigh-sensitive C-reactive protein (hs-CRP)\u003c\/strong\u003e, a biomarker of low-grade inflammation involved in atherosclerotic disease progression. This suggests the drug may offer \u003cstrong\u003eanti-inflammatory benefits\u003c\/strong\u003e in addition to its lipid-lowering effects\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eA Remarkable Response\u003c\/h3\u003e\n\n\u003cp\u003eIn this patient, bempedoic acid reduced LDL cholesterol by \u003cstrong\u003eover 80% compared to her initial LDL values\u003c\/strong\u003e (from 162 mg\/dl down to 34 mg\/dl). This is particularly notable because relatively high inter-individual variation in LDL lowering — ranging from \u003cstrong\u003e0% to over 80%\u003c\/strong\u003e — has been described in previous studies. Similar variability has been reported with statins, which may result from genetic polymorphisms that modulate cholesterol homeostasis. In this context, the patient appears to be a \u003cstrong\u003e\"hyper-responder\" to bempedoic acid\u003c\/strong\u003e, achieving both highly effective LDL reduction and favorable plaque modification.\u003c\/p\u003e\n\n\u003cp\u003eThe authors note that future studies, like the ongoing \u003cstrong\u003eLOCATE trial\u003c\/strong\u003e (available at https:\/\/drks.de\/search\/de\/trial\/DRKS00031954), are warranted to investigate the potential of bempedoic acid and other lipid-lowering or anti-inflammatory drugs on plaque modification through multicenter serial CCTA studies.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis case report carries several important messages for patients and their doctors:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStatin intolerance is real and manageable.\u003c\/strong\u003e Patients who experience muscle pain, weakness, or other side effects from statins should not simply stop treatment without discussing alternatives with their doctor. There are effective non-statin options available.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBempedoic acid is a viable alternative.\u003c\/strong\u003e For patients who cannot tolerate multiple statins or ezetimibe, bempedoic acid can dramatically lower LDL cholesterol — in some cases, as this report shows, by more than 80%.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLower LDL can translate into visible plaque changes.\u003c\/strong\u003e This case provides visual evidence that aggressive LDL lowering with bempedoic acid was accompanied by shrinkage of the dangerous, soft (low-attenuation) plaque component in the coronary arteries — the type of plaque most likely to rupture and cause heart attacks.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCT imaging can track treatment success.\u003c\/strong\u003e Serial CCTA scans allow doctors to see not just whether a blockage is present, but whether plaque composition is changing in response to treatment — moving from dangerous soft plaque toward more stable calcified plaque.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIndividual responses vary.\u003c\/strong\u003e Not every patient will respond as dramatically as this patient did. LDL lowering with bempedoic acid can range from 0% to over 80%, and genetic factors may play a role. Regular monitoring is essential.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations: What This Case Couldn't Prove\u003c\/h2\u003e\n\n\u003cp\u003eAs a case report — a detailed description of a single patient — this study has important limitations that patients should understand:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSingle patient experience:\u003c\/strong\u003e Results from one patient cannot be generalized to all patients. What worked spectacularly for this individual may not work the same way for others.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConfounding prior treatments:\u003c\/strong\u003e The patient had been on statins and ezetimibe for a considerable time before starting bempedoic acid. These earlier treatments may have contributed to some of the plaque changes observed, although they were not sufficient to achieve LDL targets on their own.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTreatment sequencing:\u003c\/strong\u003e Bempedoic acid was tried before PCSK9 inhibitors due to the patient's preference for oral (pill) over subcutaneous (injection) therapy and due to cost issues. In Germany's reimbursement system, proof of administration of all possible oral lipid-lowering treatments — including statins, ezetimibe, and bempedoic acid — is required before approval of PCSK9 inhibitor coverage.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo control group:\u003c\/strong\u003e There is no comparison patient or group to determine how much of the plaque change was due specifically to bempedoic acid versus other factors.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this case and the research it builds upon, patients with coronary artery disease and cholesterol management challenges should consider the following:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your numbers.\u003c\/strong\u003e The current guideline recommends an LDL goal of \u003cstrong\u003ebelow 55 mg\/dl\u003c\/strong\u003e for patients at very high risk, and a reduction of \u003cstrong\u003emore than 50% from baseline\u003c\/strong\u003e. Ask your doctor what your target is and track your progress.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDon't suffer in silence.\u003c\/strong\u003e If you experience muscle pain, weakness, unsteadiness, or other symptoms while taking statins, report them to your healthcare provider. There are alternatives — including bempedoic acid, ezetimibe, and PCSK9 inhibitors — that may work without the same side effects.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand your options.\u003c\/strong\u003e Bempedoic acid is taken as a pill (180 mg daily in this case), while PCSK9 inhibitors are injections. Cost, insurance coverage, and personal preference all play a role in choosing the right treatment. Ask your doctor about what is covered and what makes sense for your situation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about imaging.\u003c\/strong\u003e If you have known coronary artery disease and are starting or changing lipid-lowering therapy, ask whether follow-up CCTA imaging might be appropriate to monitor plaque changes over time. This is especially relevant if you have recurrent or new symptoms.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTake inflammation seriously.\u003c\/strong\u003e The ability of bempedoic acid to reduce hs-CRP (a marker of inflammation) suggests that managing inflammation — not just cholesterol — may be an important part of protecting your heart. Ask your doctor about inflammatory markers and what they mean for your risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStay patient and persistent.\u003c\/strong\u003e Achieving LDL targets may require trying multiple medications or combinations. This patient's journey spanned nearly 6 years (from March 2017 to December 2022) before her cholesterol reached the recommended target. Don't get discouraged — effective options exist.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe authors note that this research was conducted in accordance with ethical guidelines. Ethical review and approval were not required for the study on human participants in accordance with local legislation and institutional requirements, and the patient provided written informed consent to participate and for publication of potentially identifiable images or data, in line with COPE guidelines.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eI can't take statins because of muscle pain. Is there another cholesterol medication that might work for me?\u003c\/h3\u003e\n\u003cp\u003eYes. Bempedoic acid is a non-statin pill that works differently from statins and has a low risk of muscle side effects. In this case report, it lowered LDL cholesterol from 162 to 34–38 mg\/dl in a statin-intolerant patient. Talk to your doctor about whether it may be an option for you.\u003c\/p\u003e\n\u003ch3\u003eMy LDL cholesterol is high despite taking statins and ezetimibe. What can I do?\u003c\/h3\u003e\n\u003cp\u003eIn this report, a patient who could not tolerate statins or ezetimibe was switched to bempedoic acid. Her LDL dropped from over 160 to below 40 mg\/dl, and her dangerous soft plaque shrank on CT scans. Ask your doctor if bempedoic acid might help you reach your LDL target.\u003c\/p\u003e\n\u003ch3\u003eWhat is bempedoic acid and how does it lower cholesterol?\u003c\/h3\u003e\n\u003cp\u003eBempedoic acid is a pill that blocks an enzyme upstream of the one statins target, reducing cholesterol production in the liver. It is associated with fewer muscle side effects than statins. In studies, it lowers LDL by about 23% when used alone, and by over 40% when combined with ezetimibe.\u003c\/p\u003e\n\u003ch3\u003eWill taking bempedoic acid shrink the dangerous plaque in my heart arteries?\u003c\/h3\u003e\n\u003cp\u003eThis case report showed that in one patient, bempedoic acid dramatically lowered LDL and, on follow-up CT scans after 20 months, the soft, dangerous plaque in a coronary artery was barely detectable. However, this is a single case, so similar results are not guaranteed for everyone.\u003c\/p\u003e\n\u003ch3\u003eHow quickly did the patient's cholesterol improve with bempedoic acid?\u003c\/h3\u003e\n\u003cp\u003eIn this case, the patient started bempedoic acid in 2021. By November 2021, her LDL had dropped to 34 mg\/dl. In December 2022, it was still low at 38 mg\/dl. Her follow-up CT scan showed plaque stabilization. But response varies widely between individuals.\u003c\/p\u003e\n\u003ch3\u003eWhat is low-attenuation plaque on a coronary CT scan and why does it matter?\u003c\/h3\u003e\n\u003cp\u003eLow-attenuation plaque is the soft, dangerous type of plaque in artery walls that is more prone to rupture and cause heart attacks. It is a stronger predictor of death or heart attack than the degree of narrowing. This case showed that aggressive LDL lowering reduced that soft plaque component.\u003c\/p\u003e\n\u003ch3\u003eAre there limitations to this case report about bempedoic acid and plaque shrinkage?\u003c\/h3\u003e\n\u003cp\u003eYes. This is a single patient's experience, so it cannot be generalized. The patient had previously taken statins and ezetimibe, and there was no control group. Also, bempedoic acid was tried before PCSK9 inhibitors. These factors make it impossible to prove exactly what caused the plaque changes.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003eThis patient-friendly article is based on the following peer-reviewed research:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOriginal Title:\u003c\/strong\u003e Case report: Strong low-density-cholesterol reduction accompanied by shrinkage of low-attenuation coronary plaque during lipid-lowering treatment with bempedoic acid — serial evaluation by coronary computed tomography angiography\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAuthors:\u003c\/strong\u003e Grigorios Korosoglou, Alexander Giesen, Eva Geiss, and Ksenija Stach\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJournal:\u003c\/strong\u003e Frontiers in Cardiovascular Medicine, Volume 10, Article 1203832\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePublication Date:\u003c\/strong\u003e August 4, 2023\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.3389\/fcvm.2023.1203832\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not constitute medical advice. Patients should consult their healthcare providers about their individual treatment options.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47415300194460,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.de\/products\/how-a-cholesterol-medication-that-bypasses-statin-side-effects-shrunk-dangerous-heart-plaque-a-patients-success-story","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}